HealthWell Foundation

Overview

HealthWell Foundation is an independent nonprofit charitable patient-assistance foundation, not a commercial copay-card processor. Its role in the access stack is to operate disease-specific funds that help underinsured patients pay medication copayments, insurance premiums, deductibles, and related treatment cost-sharing.

For a biopharma launch team, HealthWell matters most where government-insured or underinsured patients need a compliant financial-assistance path that cannot be handled through manufacturer copay cards. The foundation reports a 100 disease-area safety-net portfolio, including more than 40 oncology funds, and says it has provided more than $5.2 billion in cumulative financial support through more than 2.2 million grants.

Manufacturer Fit

HealthWell is best understood as charitable-assistance infrastructure adjacent to a launch plan, not as an RFP substitute for a hub, copay-card processor, or PAP administrator. Manufacturers should evaluate HealthWell by disease-fund availability, funding capacity, patient eligibility rules, specialty-pharmacy workflow, and compliance guardrails.

The relevant question is whether a disease area has a HealthWell fund with adequate capacity and whether the patient-support ecosystem knows how to route eligible patients without compromising charitable-foundation independence.

Affordability Capability Model

The framework below standardizes how Rx Almanac evaluates copay-financial-assistance capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, HealthWell Foundation is evaluated as independent nonprofit charitable patient-assistance foundation, not a commercial copay-card processor.

Capability	Buyer should compare	HealthWell Foundation readout
Copay card design and claims adjudication	Program setup, BIN/PCN/group logic, real-time pharmacy adjudication, benefit limits, reversals, and claims reconciliation.	Core coverage workflow. HealthWell reports 100 disease areas and more than 40 oncology funds. Not the right fit. These belong with commercial affordability vendors, not HealthWell’s charitable-foundation model.
PAP, foundation, and free-drug support	Eligibility screening, income verification, foundation routing, free-drug workflows, renewals, and bridge program administration.	Core eligibility workflow. HealthWell administers disease-specific grants for underinsured patients facing medical hardship. Core affordability operations. Public materials describe medication copayment, insurance premium, deductible, and treatment cost-sharing support.
Accumulator, maximizer, and affordability controls	Detection and mitigation of accumulator/maximizer exposure, plan edits, alternative funding, and program rule tuning.	Not the main buying reason for HealthWell Foundation; validate only if the SOW includes accumulator, maximizer, and affordability controls.
Eligibility, enrollment, and patient communications	Digital enrollment, status updates, patient support, card activation, reminders, and multilingual service workflows.	Not the main buying reason for HealthWell Foundation; validate only if the SOW includes eligibility, enrollment, and patient communications.
Payment rails, debit/card, and pharmacy integration	Card issuing, debit rails, reimbursement, pharmacy switch connectivity, payment settlement, and vendor integrations.	Network connection. HealthWell operates patient, provider, and pharmacy portals and highlighted specialty-pharmacy CPAP workflow at Asembia AXS26.
Compliance, reporting, and GTN visibility	Program controls, audit trails, utilization reports, budget visibility, GTN impact, and manufacturer dashboards.	Core diligence item. Public materials emphasize independent charitable status and compliance with federal patient-assistance rules.

Buyer Fit

• When it belongs in the set: Include HealthWell in access planning when a therapy area has underinsured, Medicare, or high-cost specialty patients who may need independent charitable support.
• Therapy and product fit: Current public signals are strongest in oncology and high-cost specialty conditions, with HealthWell reporting more than 40 oncology funds and broad disease-fund coverage.
• Operating fit: HealthWell should sit in the foundation-referral and financial-navigation workstream alongside hub, specialty-pharmacy, and patient-assistance vendors.
• Validate before launch: Confirm fund status, capacity, eligible cost categories, renewal timing, portal workflow, specialty-pharmacy process, and legal/compliance rules for manufacturer donors.

Differentiators

• Large independent foundation scale: HealthWell reports more than $5.2 billion in cumulative support through more than 2.2 million grants.
• Current 2025 operating scale: HealthWell reported more than $1.1 billion in medication copayment and premium assistance through more than 440,000 grants to more than 420,000 underinsured patients in 2025.
• Oncology depth: The foundation says it has supported more than 496,000 cancer patients with more than $2.6 billion through more than 757,000 grants.
• Specialty-pharmacy relevance: At Asembia AXS26, HealthWell moderated a panel on the role of specialty pharmacies when working with charitable patient assistance programs.
• Public charity efficiency signal: HealthWell was ranked #17 on Forbes’ 2025 list of America’s Top 100 Charities and recognized for 100% fundraising efficiency.

RFP Questions

• Which disease funds are open today, and how often do they open, close, or change award rules?
• Which patient cost categories are covered: medication copayments, premiums, deductibles, travel, supplies, or other treatment-related costs?
• How should hub, specialty-pharmacy, and provider teams route patients without compromising charitable-foundation independence?
• What portal access, reimbursement-card workflow, and status data are available to patients, providers, and pharmacies?
• What compliance rules govern manufacturer donations, disease-fund creation, communications, and reporting?

Recent Activity

• 2026: HealthWell announced plans to showcase its disease-fund portfolio at the 2026 ASCO Annual Meeting, including more than 40 oncology funds.
• 2026: HealthWell moderated an Asembia AXS26 panel on specialty pharmacies working with charitable patient assistance programs and the compliance risks around alternative funding programs.
• 2026: HealthWell published 2025 preliminary operating results, reporting $530 million in financial support received and more than $1.1 billion in assistance awarded.
• 2025: HealthWell opened or reopened funds including Neuroendocrine Tumors, Parkinson’s disease, Bronchiectasis, and ACA marketplace premium assistance.